Liang Michael, Devlin Gerard, Pasupati Sanjeevan
Department of Cardiology, Waikato Hospital, Hamilton, New Zealand.
J Invasive Cardiol. 2012 Apr;24(4):173-6.
Transcatheter aortic valve implantation (TAVI) has been performed at Waikato Hospital for high-risk severe symptomatic aortic stenosis patients who are considered unsuitable for conventional cardiac surgery for the last 3 years. The Medtronic CoreValve (MCV) is a self-expandable device, while the Edwards SAPIEN valve (EV) requires the use of a balloon to expand the device. This observational study reports and compares the incidence of heart block in both Medtronic and Edwards transcatheter valves.
All patients who underwent TAVI between the periods of 28 August 2008 and 27 July 2011 were included in this study. Preprocedure and daily postprocedure until discharge electrocardiograms (ECG) were obtained prospectively. New onsets of significant atrioventricular (AV) and bundle branch blocks were recorded. Patients with existing pacemaker and those who did not survive the procedure were excluded.
Sixty patients underwent TAVI during the study period, of whom 40 (67%) and 20 (33%) patients had MCV and EV implanted, respectively. Seven patients were excluded from the analysis; 38 MCV and 15 EV patients fulfilled the criteria for analysis. Mean age was 80 ± 7 years, 57% were male. Five patients (9%) required permanent pacemaker (PPM) implantation, which occurred exclusively post MCV TAVI (MCV vs EV: 13% vs 0%, respectively; P=.02). The indications of PPM were complete heart block in 3 patients (60%), Mobitz II second-degree heart block in 1 patient (20%), and symptomatic sick sinus syndrome in 1 patient (20%). The incidence of left bundle branch block (LBBB) was increased after the TAVI procedure and was more significant with MCV implants (MCV vs EV: 42% vs 8%, respectively; P<.01). Of note, 2 of the 5 patients (40%) with pre-existing right bundle branch block (RBBB) who underwent TAVI required PPM (P=.01).
MCV implantation is associated with a higher incidence of significant AV block requiring PPM implantation and LBBB compared to EV. The overall rate of PPM requirement post MCV TAVI is, however, lower than previously published data. Pre-existing RBBB may help in predicting the likelihood of developing significant AV block.
在过去3年里,怀卡托医院已对那些被认为不适合进行传统心脏手术的高危重度有症状主动脉瓣狭窄患者实施经导管主动脉瓣植入术(TAVI)。美敦力CoreValve(MCV)是一种自膨胀装置,而爱德华兹SAPIEN瓣膜(EV)需要使用球囊来扩张该装置。本观察性研究报告并比较了美敦力和爱德华兹经导管瓣膜中心脏传导阻滞的发生率。
本研究纳入了2008年8月28日至2011年7月27日期间接受TAVI的所有患者。前瞻性地获取术前及术后直至出院的每日心电图(ECG)。记录显著房室(AV)和束支传导阻滞的新发病例。排除已有起搏器的患者以及手术未存活的患者。
在研究期间,60例患者接受了TAVI,其中分别有40例(67%)和20例(33%)患者植入了MCV和EV。7例患者被排除在分析之外;38例MCV患者和15例EV患者符合分析标准。平均年龄为80±7岁,57%为男性。5例患者(9%)需要植入永久性起搏器(PPM),均仅发生在MCV TAVI术后(MCV与EV相比:分别为13%与0%;P = 0.02)。PPM植入的指征为3例患者(60%)发生完全性心脏传导阻滞,1例患者(20%)发生莫氏Ⅱ型二度心脏传导阻滞,1例患者(20%)发生有症状的病态窦房结综合征。TAVI术后左束支传导阻滞(LBBB)的发生率增加,且在植入MCV的患者中更显著(MCV与EV相比:分别为42%与8%;P < 0.01)。值得注意的是,5例术前已有右束支传导阻滞(RBBB)且接受TAVI的患者中有2例(40%)需要植入PPM(P = 0.01)。
与EV相比,植入MCV后需要植入PPM的显著AV阻滞和LBBB的发生率更高。然而,MCV TAVI术后PPM的总体需求率低于先前发表的数据。术前已有RBBB可能有助于预测发生显著AV阻滞的可能性。